Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10. The study tested Epcoritamab, which is a bispecific antibody, in combination with R-ICE chemotherapy.
The study was focused on adult patients with relapsed or refractory diffuse large B-cell lymphoma who could undergo autologous stem cell transplantation. The results revealed that the combination therapy achieved an overall response rate of 87%. Moreover, 65% of patients had a complete response where no signs of cancer remained. On the other hand, 23% had a partial response.
A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.
The treatment was regarded as generally well-tolerated, and the most common side effects were low white blood cells, anemia, and low platelets. These results are promising for high-risk patients who need new options. The combination may help more patients reach a stem cell transplant, which can be curative. However, this therapy is still investigational and not yet approved for this use.
Genmab A/S is a biotechnology company based in Denmark that develops antibody-based therapies for cancer and other diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
